Are TNF inhibitors still the agent of choice for RA?

被引：0
|
作者：
Taylor, Peter C. [1 ]
机构：
[1] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England
来源：
NATURE REVIEWS RHEUMATOLOGY | 2023年
关键词：
RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; METHOTREXATE; COMBINATION; ADALIMUMAB;
D O I：
10.1038/s41584-023-01043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Guidelines in RA treatment: concepts on safety and recomendations using anti-TNF-α inhibitors
    Diaz-Jouanen, Efrain
    Abud-Mendoza, Carlos
    Alberto Garza-Elizondo, Mario
    Medrano-Ramirez, Gabriel
    Burgos-Vargas, Ruben
    Javier Orozco-Alcala, Jose
    Francisco Pacheco-Tena, Cesar
    Pineda, Carlos
    Pozos-Espindola, Juan Carlos
    Ramos-Niembro, Francisco
    Robles-San-Roman, Manuel
    Ernesto Santana-Sahagun, Jesus
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2009, 61 (03): : 252 - 266
  • [32] TNF Inhibitors Exert a "Hidden" Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients
    Calvo Alen, Jaime
    Alio Lavin-Gomez, Bernardo
    Aurrecoechea, Elena
    Guerra Ruiz, Armando Raul
    Martinez Taboada, Victor
    Gomez Gerique, Juan
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 187 - 197
  • [33] RHEUMATOID ARTHRITIS When TNF inhibitors fail in RA-weighing up the options
    Silva-Fernandez, Lucia
    Hyrich, Kimme
    NATURE REVIEWS RHEUMATOLOGY, 2014, 10 (05) : 262 - 264
  • [34] Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors
    Kremer, J. M.
    Tony, H.
    Tak, P. P.
    Luggen, M.
    Manette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 326 - 326
  • [35] TNF INHIBITORS ARE ASSOCIATED WITH A REDUCED RISK OF VENOUS THROMBOEMBOLISM COMPARED TO CSDMARDS IN RA PATIENTS
    Schaefer, M.
    Schneider, M.
    Graessler, A.
    Ochs, W.
    Zink, A.
    Strangfeld, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 8 - 9
  • [36] Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
    Nocturne, Gaetane
    Seror, Raphaele
    Mariette, Xavier
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02)
  • [37] Autoantibodies and thrombophilia in RA:: TNFα and TNFα blockers
    Ferraccioli, GF
    Gremese, E
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) : 613 - 615
  • [38] In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y
    Schattner, Ami
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (07) : JC83 - JC83
  • [39] Association of methotrexate(MTX), TNF-inhibitors (TNF-1) and prednisone (PRED) with risk of infection among RA patients
    Greenberg, J. D.
    Kavanaugh, A.
    Hochberg, M.
    Kremer, J. M.
    Reed, G.
    Zheng, C.
    Tindall, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 171 - 171
  • [40] Plasma VEGF decreases in RA and SpA patients who respond to treatment with TNF inhibitors.
    Hetland, ML
    Skjodt, H
    Ostergaard, M
    Nielsen, HJ
    Majgaard, O
    Johansen, JS
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S700 - S700
12345